FDA sends warning to 30 telehealth companies selling ‘illegal’ GLP-1s
The Food and Drug Administration (FDA) on Tuesday sent 30 telehealth companies warning letters about their “illegal” sales of ...
US FDA warns 30 telehealth firms over misleading ads for compounded weight-loss drugs
March 3 (Reuters) - The U.S. Food and Drug Administration has issued warning letters to 30 telehealth companies for making ...
Are You Being Misled By GLP-1 Ads? FDA Issues 30 Telehealth Companies Warning Letters
The FDA has issued warnings to 30 telehealth companies for making false or misleading claims regarding compounded GLP-1 ...
MedPage Today on MSN
FDA Warns 30 Telehealth Firms Over Compounded GLP-1 Medications
Part of "a new era of enforcement," says FDA chief ...
Is Your GLP‑1 Drug Illegal? What to Know About the FDA’s New Warning to 30 Companies
The FDA issued warning letters to 30 telehealth companies over misleading claims about compounded versions of popular ...
Fierce Pharma
FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters
The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent ...
Pharmaceutical Commerce
FDA Issues 30 Warning Letters to Telehealth Firms Over Misleading Compounded GLP-1 Marketing
Thirty telehealth firms received warning letters for illegal promotion of compounded semaglutide/tirzepatide, reflecting an expanded enforcement tempo that now surpasses the prior decade’s letter ...
ConsumerAffairs
FDA warns telehealth companies about misleading GLP-1 drug claims
The FDA has issued 30 warning letters to telehealth companies over misleading claims about compounded GLP-1 drugs. Regulators say some companies im ...
European Medical Journal
FDA Warns 30 Telehealth Companies Against Illegal GLP-1 Marketing
The FDA has issued warning letters to 30 telehealth companies for reportedly making false claims about GLP-1 products. Read more.
Becker's Hospital Review
FDA sends Novo Nordisk 2nd warning over GLP-1 ads
FDA sends Novo Nordisk 2nd warning over GLP-1 ads for misleading claims in Ozempic promotion and risk disclosure violations.
Becker's Hospital Review
FDA warns 30 telehealth firms over compounded GLP-1 claims
The FDA has issued 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products on their websites. The letters cite violations including claims ...
Sierra Sun Times
FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s
March 4, 2026 - The U.S. Food and Drug Administration on Tuesday announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 ...